Released Nov 9, 2026, before the open
10-Q filed Nov 9, 2026, 40 days after period end · 0001628280-26-072169
What the release said
Bicara achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC and expects topline results from an interim analysis in mid-2027.¶1¶2
Net loss totaled $71.2 million for the third quarter of 2026 compared to $36.3 million for the third quarter of 2025.¶3
Research and development expenses were $56.5 million and general and administrative expenses were $19.2 million for the third quarter of 2026.¶4¶5
Cash, cash equivalents and marketable securities were $442.3 million as of September 30, 2026, expected to fund operations into the first half of 2029.¶6
- Net loss, Q3 2026
- $71.2 million Net loss totaled $71.2 million for the third quarter of 2026 compared to $36.3 million for the third quarter of 2025.¶3
- Research and development expenses, Q3 2026
- $56.5 million Research and development expenses were $56.5 million for the third quarter of 2026 as compared to $33.0 million for the third quarter of 2025.¶4
- General and administrative expenses, Q3 2026
- $19.2 million General and administrative expenses were $19.2 million for the third quarter of 2026 as compared to $7.7 million for the third quarter of 2025.¶5
- Cash, cash equivalents and marketable securities
- $442.3 million As of September 30, 2026, compared to $414.8 million as of December 31, 2025.¶6
- Research and development expenses, Q3 2025
- $33.0 million Comparison figure for the third quarter of 2025 as stated in the filing.¶4
- General and administrative expenses, Q3 2025
- $7.7 million Comparison figure for the third quarter of 2025 as stated in the filing.¶5
Same quarter
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Net Income | -$71.25M | -$36.33M | -$17.48M | -$22.85M |
| EPS Diluted | -$1.04 | -$0.67 | -$1.60 | -$38.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR